Header

Cutaneous Skin Cancer Clinical Trials

Category:Adult
Status:Active

Displaying all 15 Trial

Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

This randomized phase II/III trial studies the side effects and best dose of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating pati...

Diagnosis: Melanoma, Cutaneous Skin Cancer

Phase: 2 / 3

Protocol Number: 15-724

Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

This partially randomized phase I/II trial studies the side effects and best dose of dabrafenib, trametinib, and navitoclax and to see how well they work in treating patients with v-raf murine sarc...

Diagnosis: Cutaneous Skin Cancer

Phase: 1 / 2

Protocol Number: 18-716 & 13-424

A Study of DCC-2701 in Participants With Advanced Solid Tumors

The main purpose of this study is to investigate the safety of the investigational drug DCC-2701 and whether it will work to help people who have advanced solid tumors or cancer that has spread to ...

Diagnosis: Cutaneous Skin Cancer

Phase: 1

Protocol Number: 14-031

Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

This phase I trial studies the side effects and best dose of heat shock protein (Hsp)90 inhibitor AT13387 when given together with dabrafenib and trametinib in treating patients with melanoma or so...

Diagnosis: Cutaneous Skin Cancer

Phase: 1

Protocol Number: 14-186

Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma

The Valchlor PROVe study is a multi-center, prospective, observational, US-based drug study that longitudinally follows patients with MF-CTCL who are receiving therapy with Valchlor. Patients will ...

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 15-217

Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

This pilot phase II trial studies how well nelfinavir mesylate works in treating patients with kaposi sarcoma. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes...

Diagnosis: Cutaneous Skin Cancer, Other Trials

Phase:

Protocol Number: 16-388

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

The purpose of this trial is to assess the efficacy and safety of E7777 (improved purity ONTAK) in patients with persistent and recurrent cutaneous T-cell lymphoma. A lead-in dose-finding part will...

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 17-529

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

This phase II trial studies how well talimogene laherparepvec works and nivolumab in treating patients with lymphomas that do not responded to treatment or non-melanoma skin cancers that have sprea...

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 17-753

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

The primary objective is to estimate the overall response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced BCC (group 2) when treated with REGN28...

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 17-314

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

To assess the efficacy, safety and pharmacokinetics in subjects treated with CD11301 gel vs. placebo for early stage CTCL (IA, IB, or IIA).

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 17-649

Adjuvant Avelumab in Merkel Cell Cancer

This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery with or without radiation ...

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 18-148

Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome

This phase II trial studies how well pembrolizumab and interferon gamma-1b work in treating patients with stage IB-IVB mycosis fungoides and sezary syndrome that has come back or has not responded ...

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 18-079

Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

This is a phase 1b/2, open-label, multicenter trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral AST-008 injections alo...

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 18-584

This Study Evaluates KRT-232, a Novel Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients With (p53WT) Merkel Cell Carcinoma Who Have Failed Anti-PD-1/ PD-L1 Immunotherapy

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or ...

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 19-014

SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) sub...

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 18-563

'